Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 755,342,208
  • Shares Outstanding, K 949,316
  • Annual Sales, $ 34,124 M
  • Annual Income, $ 5,240 M
  • EBIT $ 13,467 M
  • EBITDA $ 14,994 M
  • 60-Month Beta 0.41
  • Price/Sales 22.15
  • Price/Cash Flow 100.67
  • Price/Book 50.90

Options Overview Details

View History
  • Implied Volatility 26.71% ( -2.54%)
  • Historical Volatility 31.70%
  • IV Percentile 21%
  • IV Rank 13.01%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.48
  • Today's Volume 16,175
  • Volume Avg (30-Day) 38,860
  • Put/Call OI Ratio 0.89
  • Today's Open Interest 323,961
  • Open Int (30-Day) 344,832

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.49
  • Number of Estimates 8
  • High Estimate 5.58
  • Low Estimate 5.37
  • Prior Year 2.49
  • Growth Rate Est. (year over year) +120.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
740.01 +7.52%
on 11/25/24
846.46 -6.00%
on 12/04/24
+47.66 (+6.37%)
since 11/22/24
3-Month
711.40 +11.85%
on 11/18/24
939.30 -15.29%
on 09/25/24
-128.76 (-13.93%)
since 09/24/24
52-Week
567.64 +40.17%
on 12/26/23
972.53 -18.19%
on 08/22/24
+225.28 (+39.50%)
since 12/22/23

Most Recent Stories

More News
Is Eli Lilly an Undervalued Growth Stock to Buy Now?

Eli Lilly (NYSE: LLY) is generating billions in cash flow growth due to product innovation.

LLY : 795.67 (-0.08%)
1 Spectacular Growth Stock That Could Join Nvidia, Tesla, Apple, and Others in the $1 Trillion Club

This growth stock is expected to experience a surge in revenue, profit, and cash flow in the upcoming years.

NVDA : 140.22 (+0.39%)
AAPL : 258.20 (+1.15%)
TSLA : 462.28 (+7.36%)
LLY : 795.67 (-0.08%)
Company News for Dec 24, 2024

Shares of Walmart (WMT) fell 2.1% after the U.S. consumer finance watchdog accused the company and Branch Messenger of imposing accounts on over a million delivery drivers, leading to more than $10 million...

QCOM : 159.36 (+0.71%)
LLY : 795.67 (-0.08%)
WMT : 92.68 (+2.58%)
HMC : 27.25 (+1.19%)
Stock Index Futures Gain in Thin Pre-Christmas Trade

March S&P 500 E-Mini futures (ESH25) are up +0.14%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.18% this morning ahead of a holiday-shortened pre-Christmas trading session.

AVGO : 239.68 (+3.15%)
NEUE : 7.54 (+74.94%)
EVTL : 8.96 (+20.75%)
INSW : 36.92 (+9.30%)
ESH25 : 6,098.00s (+1.03%)
QCOM : 159.36 (+0.71%)
GFS : 44.64 (+1.39%)
LLY : 795.67 (-0.08%)
X : 31.97 (+1.91%)
NQH25 : 22,028.50s (+1.27%)
VTY.LN : 547.500 (-16.28%)
RCEL : 12.91 (+9.87%)
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III

Novo Nordisk NVO has achieved the primary endpoint in a late-stage study evaluating its next-gen subcutaneous obesity treatment candidate, CagriSema. The results showed that treatment with the candidate...

NVO : 87.37 (-1.51%)
MRK : 99.45 (+0.08%)
LLY : 795.67 (-0.08%)
AMGN : 264.49 (+0.19%)
3 Big-Name Stocks Just Announced Big-Time Dividend Increases

Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments.

PCAR : 105.18 (+0.46%)
MA : 535.71 (+1.28%)
V : 320.65 (+1.08%)
LLY : 795.67 (-0.08%)
SPY : 601.30 (+1.11%)
Novo Nordisk Shares Rebound After Friday’s $90B Wipeout: Retail, Analysts See Opportunity

AlphaValue/Baader Europe reportedly argued that Friday’s reaction was “materially overdone,” considering CagriSema’s potential $20 billion peak sales.

NVO : 87.37 (-1.51%)
LLY : 795.67 (-0.08%)
Better Buy: Eli Lilly or Novo Nordisk?

Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.

NVO : 87.37 (-1.51%)
LLY : 795.67 (-0.08%)
Stocks Set to Open Mixed as Bond Yields Climb, U.S. Economic Data in Focus

March S&P 500 E-Mini futures (ESH25) are down -0.14%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.12% this morning as Treasury yields climbed at the start of a holiday-shortened week, with investors...

ENPH : 73.28 (+0.38%)
NVDA : 140.22 (+0.39%)
DESP : 19.45 (-0.05%)
MU : 89.28 (-0.49%)
RUM : 12.68 (-2.69%)
ESH25 : 6,098.00s (+1.03%)
NOVOB.C.DX : 625.800 (+6.01%)
QCOM : 159.36 (+0.71%)
X : 31.97 (+1.91%)
LLY : 795.67 (-0.08%)
NQH25 : 22,028.50s (+1.27%)
AVO : 14.39 (-0.35%)
Does This News From the FDA Make Eli Lilly a Buy for 2025?

Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly...

LLY : 795.67 (-0.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 810.56
2nd Resistance Point 804.16
1st Resistance Point 799.91
Last Price 795.67
1st Support Level 789.26
2nd Support Level 782.86
3rd Support Level 778.61

See More

52-Week High 972.53
Fibonacci 61.8% 817.86
Last Price 795.67
Fibonacci 50% 770.09
Fibonacci 38.2% 722.31
52-Week Low 567.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar